R&D Ending trial-and-error: How psychedelics and precision medic... The next phase of psychiatry must go toward treatments that are not only novel, but practical, personalised, and accessible.
R&D Regulatory setback or scientific signal? The case for human-... Exploring a systemic challenge in translating biological promise into reliable human efficacy and safety.
R&D BIO-Europe Spring 2026: In conversation with Robert Jacks Robert Jacks, CEO of Sparrow Pharmaceuticals, discusses the company’s work in the cardiometabolic space.
R&D Longevity is not a consumer trend, but a pipeline strategy p... Longevity is being framed as a consumer movement when, in reality, it is a pharmaceutical pipeline challenge.
R&D Making AI work where it matters, with Rob DiCicco Rob DiCicco, vice president of portfolio management at Transcelerate Biopharma Inc, discusses barriers and the breakthroughs in making AI work.
R&D Beyond GLP-1: Preclinical hurdles and solutions for next-gen... The development experience with GLP-1 analogues offers critical insights for navigating ADME challenges in contemporary peptide programmes.
Oncology ASCO 2026: All about DNA damage response, with Luke Piggot Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
